Key findings: The research showed that for the purposes of the National HPV Vaccination program, the vast majority of each stakeholder group would prefer the NSW government to use the current HPV vaccine of the time (Gardasil ®), that provided protection against cervical cancer and genital warts, over an alternative HPV vaccine that provided protection against cervical cancer but not genital warts. The research also showed strong support for the Federal Government's National HPV Vaccination program and a series of other findings of interest.
Outcomes: CSL used the results to illustrate a strong preference for their HPV vaccine (Gardasil ®) to relevant health professionals and government decision makers. As a part of this process the results were presented in poster and oral form at two conferences during 2008.
- 3rd Annual AOGIN Conference 2008 in Seoul, South Korea (Asia-Oceania Research Organisation in Genital Infections and Neoplasia)
- 11th PHAA National Immunisation Conference 2008 in Queensland (The Public Health Association of Australia)
